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a b s t r a c t
The Schistosoma mansoni venom allergen-like (SmVAL) protein family consists of 29 members, each pos-
sessing a conserved a-b-a sandwich tertiary feature called the Sperm-coating protein/Tpx-1/Ag5/PR-1/
Sc7 (SCP/TAPS) domain. While the SmVALs have been found in both excretory/secretory (E/S) products
and in intra/sub-tegumental (non-E/S) fractions, the role(s) of this family in host/parasite relationships
or schistosome developmental processes remains poorly resolved. In order to begin quantifying SmVAL
functional diversity or redundancy, dissecting the specific activity (ies) of individual family members is
necessary. Towards this end, we present the characterisation of SmVAL9; a protein previously found
enriched in both miracidia/sporocyst larval transformation proteins and in egg secretions. While our
study confirms that SmVAL9 is indeed found in soluble egg products and miracidia/sporocyst larval trans-
formation proteins, we find it to be maximally transcribed/translated in miracidia and subsequently
down-regulated during in vitro sporocyst development. SmVAL9 localisation within sporocysts appears
concentrated in parenchymal cells/vesicles as well as associated with larval germinal cells. Furthermore,
we demonstrate that egg-derived SmVAL9 carries an N-linked glycan containing a schistosome-specific
difucosyl element and is an immunogenic target during chronic murine schistosomiasis. Finally, we dem-
onstrate that recombinant SmVAL9 affects the expression of extracellular matrix, remodelling matrix
metalloproteinase (MMP) and tissue inhibitors of metalloproteinase (TIMP) gene products in both Biom-
phalaria glabrata embryonic cell (BgMMP1) and Mus musculus bone marrow-derived macrophage
(MmMMP2, MmMMP9, MmMMP12, MmMMP13, MmMMP14, MmMMP28, TIMP1 and TIMP2) in vitro
cultures. These findings importantly suggest that excreted/secreted SmVAL9 participates in tissue
reorganisation/extracellular matrix remodelling during intra-mammalian egg translocation, miracidia
infection and intra-molluscan sporocyst development/migration.
 2014 The Authors. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. This is
an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
1. Introduction
It has long been appreciated that schistosomes are capable of
establishing long-lasting relationshipswith their intermediate snail
and definitive mammalian hosts (Basch, 1991). While the molecu-
lar basis for these parasite/host interactions is not fully understood
(Geyer and Hoffmann, 2012), a variety of schistosome biomolecules
including glycans (Hokke and Deelder, 2001; van Die and
Cummings, 2010), proteins (Han et al., 2009), small metabolites
(Da’dara and Skelly, 2011) and even microRNAs (miRNAs) (Cheng
et al., 2013) are postulated to be involved. As schistosomiasis
represents an important neglected tropical disease (NTD) targeted
by international agencies for global elimination (Barry et al.,
2013), identification and functional characterisation of the specific
biomolecules utilised by schistosomes to orchestrate sustainable
host interactions represents a rational approach in progressing
novel chemotherapeutic/immunoprophylactic intervention
strategies.
Recent studies in our laboratories have identified a family of
proteins, the Schistosoma mansoni Venom Allergen-Like (SmVAL)
molecules, which may be involved in parasite development and
host interrelationships (Chalmers et al., 2008; Wu et al., 2009).
The SmVALs are comprised of at least 29 members (SmVAL1–29)
and are subdivided into two major groupings: the group 1 SmVALs
(SmVAL1–5, 7–10, 12, 14–15, 18–29) and the group 2 SmVALs
http://dx.doi.org/10.1016/j.ijpara.2014.04.002
0020-7519/ 2014 The Authors. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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(SmVAL6, 11, 13, 16–17). Group 1 SmVALs display features (signal
peptides and conserved cysteines appropriately positioned for
disulphide bond formation) associated with an extracellular envi-
ronment and excretion/secretion from the parasite whereas group
2 SmVALs do not (Chalmers et al., 2008). Interestingly, this segre-
gation is not unique to schistosomes as group 1 and group 2
SmVAL homologs have also been identified in representative spe-
cies across all four platyhelminth classes (Chalmers and
Hoffmann, 2012). While basic information (localisation of tran-
script/protein to sub-surface tissues) related to group 2 SmVAL
biology is limited to SmVAL6 (van Balkom et al., 2005;
Nawaratna et al., 2011; Rofatto et al., 2012), experimental evidence
to support the excretion/secretion of group 1 SmVALs from schis-
tosomes is substantial. This includes the identification of SmVAL4,
10 and 18 in cercarial/schistosomula secretions (Curwen et al.,
2006; Farias et al., 2012), SmVAL2, 3, 5 and 9 in egg secretions
(Cass et al., 2007), SmVAL2, 3/23, 5/15, 9, 26/28, 27 and 29 from
miracidial/sporocyst secretions (Wu et al., 2009), SmVAL26/28
from egg hatching fluid/secretions (Mathieson and Wilson, 2010;
Farias et al., 2012) and SmVAL4 from cercarial infection tunnels
(Hansell et al., 2008). Despite these reports confirming the pres-
ence of group 1 SmVALs at the host/parasite interface, no study
has yet indicated a functional role for these proteins in establishing
or maintaining schistosomiasis.
Towards this end, we believe that we provide the first experi-
mental evidence that illustrates how an excreted/secreted (E/S)
group 1 SmVAL (SmVAL9) influences host cell gene expression.
While our data confirm that SmVAL9 is indeed secreted during
miracidia to sporocyst transformation (likely from parenchymal
or perikarya cells), we also show that this particular group 1 family
member is decorated by a schistosome-specific double fucose-con-
taining glycan in eggs and is immunogenic during murine schisto-
somiasis. These lifecycle expression patterns have been used to
guide host cellular studies, which demonstrate that SmVAL9
affects the expression of extracellular matrix modifying gene prod-
ucts (metalloproteinases and tissue inhibitors of metalloprotein-
ases) in both Biomphalaria glabrata embryonic (Bge) cell and Mus
musculus bone marrow-derived macrophage (BMDM/) popula-
tions. This conserved activity affecting both snail and mammalian
cells suggests that one function of SmVAL9 may be related to extra-
cellular matrix remodelling, which is fundamentally important to
schistosome lifecycle events including egg translocation, miracidia
infection and sporocyst development. Further studies are neces-
sary to understand whether this activity is an evolutionarily con-
served function for all excreted/secreted group 1 SmVALs or is
specific to egg/miracidia/sporocyst-derived SmVAL9.
2. Materials and methods
2.1. Ethics statement
All procedures performed on mice adhered to the United King-
dom Home Office Animals (Scientific Procedures) Act of 1986 as
well as the European Union Animals Directive 2010/63/EU and
were approved by Aberystwyth University’s (AU), UK ethical
review panel and the University of Wisconsin-Madison’s (UW-
Madison), USA Institutional Animal Care and Use Committee
(IACUC, assurance number A3368-01).
2.2. Parasite material
Puerto Rican (AU and Leiden University Medical Center (LUMC),
Netherlands) and NMRI (UW-Madison; University of Wisconsin,
USA) strains of S. mansoni were used in this study. Cercariae were
shed from B. glabrata intermediate snail hosts and used to percuta-
neously infect C57BL/6 mice (25 parasites/mouse) as previously
described (Truscott et al., 2013). Miracidia were hatched from eggs
harvested from mouse livers 7 weeks p.i., axenically isolated and
placed into in vitro culture (Yoshino and Laursen, 1995). In vitro
transforming miracidia and sporocyst stages were maintained for
different times in culture (0.5 h up to 10 days) in Chernin’s bal-
anced salt solution (Chernin, 1963) containing 1% PenStrep
(HyClone, Thermo Scientific, USA) and 0.1% glucose/trehalose
(MP Biomedicals, LLC, Solon, USA) (CBSS+) in 24-well tissue culture
plates. Soluble egg antigens (SEAs) were prepared as previously
described (Robijn et al., 2007). Equal numbers of miracidia, trans-
forming sporocysts (0.5–8 h in culture) and fully transformed spo-
rocysts (>24 h in culture) were removed from culture wells, rinsed
5x in CBSS + followed by 1x in snail PBS (sPBS, pH 7.2) and solubi-
lised in SDS sample buffer (Novagen, EMD Millipore Corporation,
USA). These particular samples were subjected to one freeze/
thaw/vortex cycle, heated to 95 C for 5 min, centrifuged at
16,000 g for 2 min and stored at 80 C until needed. Media
(CBSS+) from 24 h miracidium/sporocyst cultures containing larval
transformation proteins (LTPs) and ciliated epidermal plates (EPs)
shed into medium at 24 h were also obtained as previously
described (Peterson et al., 2009; Wu et al., 2009). All soluble para-
site protein samples were quantified by either a bicinchoninic acid
assay (BCA, Thermo Scientific) or Bradford assay (Sigma–Aldrich,
USA).
2.3. SmVAL9 transcription profile
Data from the 37,632 element S. mansoni long-oligonucleotide
DNA microarray studies of Fitzpatrick et al. (2009) was interro-
gated to find the expression profile of SmVAL9 across 15 different
lifecycle stages. Raw and normalised fluorescent intensity values
are available via Array Express (https://www.ebi.ac.uk/arrayex-
press/) under the experimental accession number E-MEXP-2094.
2.4. Recombinant SmVAL9 expression in Escherichia coli
The full-length SmVAL9 open reading frame (minus signal pep-
tide) was amplified (forward 50-TCT AGA ATG AAA ATG AAT GAC
ACG ATT CGT G-30; reverse 50-CTC GAG TGC AGT CCT ATA CGG
TCT TTG TTC-30) from miracidium-derived cDNA (Chalmers et al.,
2008) and cloned into the pGEM-T Easy vector system (Promega,
UK). SmVAL9 inserts were excised by digestion with XbaI/XhoI
and sub-cloned with a C-terminal 6 X histidine tag into the E. coli
expression vector pET-30a (+) (Novagen; Merck Chemicals Ltd.,
UK).
The SmVAL9/pET-30a (+) construct was transformed into chem-
ically competent E. coli One Shot BL21 Star (DE3) cells (Invitrogen,
UK) and expression of recombinant (r)SmVAL9 carried out
according to the BL21 Star instruction protocol. Induced cells were
pelleted, lysed and centrifuged at 30,000g for 20 min. The resulting
rSmVAL9 enriched inclusion bodies (IBs) were purified by first
resuspending the cell pellet in wash buffer (50 mM Tris–HCl pH
8.0; 100 mM NaCl, 10 mM EDTA pH 8.0, 0.5% Triton X-100,
1.4 mM b-mercaptoethanol), followed by gentle agitation at 4 C
for 15 min. The IBs were repelleted and washed twice more as
above in buffer containing 3 M urea. Purification of rSmVAL9 was
carried out by size fractionation using a continuous elution electro-
phoresis apparatus (Model 491 Prep Cell; Bio-Rad, UK), following
the manufacturer’s instructions. Fractions containing purified rSm-
VAL9 were pooled and concentrated in a 30 kDa MWCO centrifugal
filter device (Amicon, Millipore, UK) to a final volume of 1 ml. Pro-
tein concentration was determined by the Bradford method
(Sigma–Aldrich, UK) and aliquots of rSmVAL9 were stored at -
80 C.
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2.5. Second stage rSmVAL9 purification by electro-elution
Size-fractionated rSmVAL9 was further purified by electro-elu-
tion (Model 422 Electro-Eluter; Bio-Rad) for 3 h at 60 mA in TGS
buffer (25 mM Tris–HCl, 192 mM glycine, 0.1% SDS, pH 8.3). After-
wards, both upper and lower tank buffers were replaced with TG
(25 mM Tris, 192 mM glycine, pH 8.3) and elution continued for
a further 90 min to remove the SDS. Eluted samples were pooled
and checked for purity by SDS–PAGE. The identity of rSmVAL9
was confirmed by in-gel trypsin digest (de Morree et al., 2010),
followed by mass spectrophotometric (MS) analysis of extracted
peptides by MALDI-TOF-MS and sequence identification by Mascot
database queries as described (Meevissen et al., 2011). Protein con-
centration was determined by the Bradford method (Sigma–
Aldrich) and aliquots of electro-eluted rSmVAL9 stored at 80 C.
2.6. Murine rSmVAL9 antisera production
C57BL/6 mice were injected i.p. with 15 lg of electro-eluted
rSmVAL9 (solubilised in 120 ll of TG buffer) emulsified in 80 ll
of IMJECT Alum adjuvant (Thermo Scientific). A second immunisa-
tion was carried out at day 15 and a third and final booster
delivered at day 36. Animals were sacrificed 4 days after the final
immunisation and polyclonal, anti-rSmVAL9 antisera were
obtained by cardiac puncture.
2.7. Affinity chromatography of SEA/glycopeptides
Schistosoma mansoni SEAs, protein-G Sepharose-linked 114-
4D12-A monoclonal antibody (mAb) and the 114-4D12-A-binding
SEA fraction were prepared as previously described (Robijn et al.,
2007). Cysteine residues in the affinity-purified SEA glycoproteins
(240 lg) were reduced and alkylated by mixing with 0.05 volumes
of 200 mM dithiothreitol and incubating for 30 min at 56 C. There-
after, 0.2 volumes of 200 mM iodoacetamide were added followed
by incubation for 30 min in the dark at 22 C. Subsequently, the
SEA fraction was incubated in 2 ml of 50 mM ammonium bicarbon-
ate with 4 lg of trypsin (Promega, NL) at 37 C overnight. In a sec-
ond round of mAb 114–4D12-A affinity chromatography, the
glycan epitope bearing glycopeptides within the trypsin digest
were selected and subsequently purified by Zip-TipC18 (Millipore,
NL). The glycopeptides were eluted with 50% acetonitrile, 0.1% tri-
fluoroacetic acid, dried in a stream of nitrogen and stored at -20 C
prior to further analysis by MS.
2.8. MS
For reversed-phase (RP) nano-scale liquid chromatography (LC)
ion-trap-MS/MS analysis, the glycopeptide sample was applied to a
reverse-phase column (PepMap, 3 lm, 75 lm  100 mm; Dionex/
LC Packings, NL) using an Ultimate nano-HPLC system, a Famos
autosampler, and a Switchos trap-column system (Dionex/LC Pac-
kings). The column was equilibrated at room temperature with
eluent A (0.1% formic acid in water) at a flow rate of 200 nl/min.
After injection of the sample, elution conditions were switched to
10% solvent B (95% acetonitrile, 0.1% formic acid), followed by a
gradient to 60% solvent B in 45 min and a subsequent isocratic elu-
tion of 10 min. The eluent was monitored by absorption at 215 nm.
The HPLC column was coupled to an Esquire HCT electrospray
ionisation (ESI)-ion trap-MS (Bruker Daltonics, NL) containing an
electron-transfer dissociation (ETD) module (PTM Discovery Sys-
tem™, NL). The MS instrument was operated in the positive-ion
mode with an on-line nanospray source. For electrospray (1100–
1250 V), capillaries (360 lm outer diameter (OD), 20 lm inner
diameter (ID) with a 10 lm opening) from New Objective (Cam-
bridge, MA, US) were used. The solvent was evaporated at 175 C
employing a nitrogen stream of 10 L/min. Ions from m/z 300 to
m/z 1600 were registered in the MS mode. When operated in the
auto MS/MS mode, registering ions from m/z 140 to 1800, each
MS scan was followed by the acquisition of MS/MS spectra of up
to three of the most abundant ions in the MS spectrum. For the
ETD MS/MS experiment, the selected glycopeptide ion was isolated
in the ion trap. Fluoranthene radical anions were formed by nega-
tive chemical ionisation (nCI) with methane as mediator. For the
accumulation (typical accumulation time 5 ms) of fluoranthene
reactant anions in the ion trap, the polarity was switched to nega-
tive mode. Glycopeptide cations and fluoranthene anions were
incubated in the ion trap for 70 ms, allowing electron transfer, fol-
lowed by the registration of the ETD fragment ion spectrum form/z
140 to 3000. Selected MS/MS spectra were interpreted manually
using Bruker Daltonics Data Analysis software (Bruker Daltonics).
2.9. SDS–PAGE and western blotting
SEA and rSmVAL9 were resolved by SDS–PAGE and transferred
onto polyvinyl difluoride (PVDF, Millipore, UK) membranes as
previously described (Hoffmann and Strand, 1996). Solubilised
miracidia proteins, sporocyst proteins, LTP and EP were electro-
phoresed and electroblotted onto 0.2 lm nitrocellulose mem-
branes as previously described (Wu et al., 2009). SEA or rSmVAL9
containing membranes were blocked in 50 mM Tris–HCl (pH
7.5)/0.3% Tween-20/5% skimmed milk powder before incubation
with primary antibody (anti-rSmVAL9, normal mouse serum
(NMS) or chronic mouse serum (CMS); dilutions indicated in fig-
ures) in 50 mM Tris–HCl (pH 7.5)/0.05% Tween-20/5% skimmed
milk powder/150 mM NaCl for 3 h. Blots were washed three times
in 50 mM Tris–HCl (pH 7.5) before incubating with secondary
horseradish peroxidase-conjugated anti-mouse IgG antibody
(Sigma), diluted 1:5000 for 1 h. After washing three times in
50 mM Tris–HCl, pH 7.5, blots were developed using ECL-Plus
reagent (GE Healthcare, UK).
Miracidium, sporocyst, LTP and EP containing membranes were
incubated in blocking buffer (TBST; 0.02 M Tris–HCl, 0.15 M NaCl,
pH 7.5, 0.05% Tween-20, 5% BSA) overnight at 4 C followed by
exposure to 1:1000 dilution of mouse anti-rSmVAL9 in blocking
buffer overnight at 4 C. Membranes were then rinsed three times
with TBS/0.05% Tween-20, incubated for 1 h in a 1:5000 dilution of
alkaline phosphatase-conjugated goat anti-mouse IgG (Promega
Corp., US), rinsed three times in TBS and developed using a NBT/
BCIP AP chromogenic reagent (Thermo Scientific, USA). Quantita-
tive comparisons of the steady state expression of SmVAL9 protein
in miracidia and cultured sporocysts was accomplished by process-
ing equal numbers of miracidia and sporocysts at different times
post-cultivation for western blot analyses. Immunoreactive anti-
SmVAL9 bands were scanned using a UV/colour densitometer
(UVP Bioimaging Systems, USA) employing LabWorks 4.6 software.
SmVAL9 band intensities were normalised to anti-actin (Develop-
mental Studies Hybridoma Bank; http://dshb.biology.uiowa.edu/)
densitometric values in each sample. The normalised means for
three independent experimental replicates were statistically ana-
lysed by ANOVA and Tukey’s multiple means comparisons using
GraphPad Prism (version 5).
2.10. SmVAL9 immunofluorescence analysis using scanning laser
confocal microscopy (SLCM)
Fresh miracidia and cultured sporocysts were rinsed five times
in CBSS+ on ice and fixed for 24 h in 1% PFA/1% Triton X-100
(Sigma–Aldrich) in sPBS at 4 C. After fixation, larvae were washed
five times in sPBS and once in blocking buffer (5% BSA/0.02%
sodium azide), incubated in blocking buffer for 24 h at 4 C and
exposed to anti-rSmVAL9 (1:500 dilution in sPBS) for 24 h at
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4 C. Following primary antibody treatment, parasites were
washed five times in sPBS and once in blocking buffer, and
incubated in a secondary antibody mixture containing Alexa-
fluor

488-conjugated goat anti-mouse IgG (4 mg/ml), Hoechst
33258 dye (50 mg/ml) and Alexa-fluor

546-conjugated phalloidin
(7.5 mg/ml, Invitrogen) for 1 h at 22 C in the dark. After five
washes in sPBS, parasites were mounted on glass coverslips in Vec-
tashield

mounting medium (H-100, Vector Laboratories, Inc.) and
imaged using an A1R laser scanning confocal microscope (Nikon
Instruments Inc.) capable of scanning wavelengths of 408 nm,
488 nm and 561 nm for the excitation of Hoechst dye, Alexa
Fluor

488 and Alexa Fluor

546, respectively. Negative controls
included identically processed larvae in which: (i) NMS (1:500
diluted; Sigma–Aldrich) was substituted for the anti-SmVAL9 anti-
body and (ii) only the secondary Alexa-fluor

488-conjugated goat
anti-mouse IgG antibody was used.
2.11. Bge cell/rSmVAL9 co-culture
Equal numbers of Bge cells were seeded into wells of 24-well
culture plates and treated with rSmVAL9 (0.8 lg/ml in CBSS), CBSS
alone or rSmVAL9 buffer (TG) alone in CBSS. After Bge cell cultures
were exposed to recombinant protein or buffers for 24 h at 26 C,
cells were extracted with TRIzol

reagent (Invitrogen, US) to isolate
total RNA, followed by treatment with TURBO DNA-free (Ambion,
US) to eliminate contaminating DNA. DNA-free, total RNA was then
converted to cDNA using the SuperScript II first strand synthesis
system kit (Invitrogen) as outlined by the manufacturer.
2.12. Biomphalaria glabrata matrix metalloproteinase 1 identification
A partial sequence of B. glabrata matrix metalloproteinase 1
(BgMMP1) was identified by tBLASTn searches of the dataset
‘bg_4_3_supercontigs’ from the B. glabrata genome assembly 4.3
(http://biology.unm.edu/biomphalaria-genome/index.html) using
M. musculus MMP9 (NCBI accession No. NP_038627.1) and Haliotis
diversicolor MMP1 (NCBI accession No. ABY87417.1) as query
sequences. BgMMP1 was present on Contig2072, between 36,589
and 36,897 bp. Searches were performed on 09-01-13. NCBI con-
served domain database searches (Marchler-Bauer et al., 2011)
and multiple sequence alignments (MUSCLE (Edgar, 2004)) were
performed using BgMMP1 to assess the conserved motifs/residues
characteristic of matrix metalloproteinase protein family mem-
bers. Amplification (forward 50-ATG ACA CCC TCC TGT TTC TTC
AAT CTA-30; reverse 50-TAA CTC GGT ACA CGA CCC GTA TTC CTT-
30) of a 307 bp BgMMP1 fragment (NCBI accession number
KF287725) from B. glabrata embryonic (Bge) cell cDNA confirmed
the transcription of this gene product. Molecular features of the
cloned BgMMP1 fragment are summarised in Supplementary
Fig. S1 and Supplementary Table S1.
2.13. ELISA
Sera from experimentally infected mice were assessed for total
IgG response to rSmVAL9 by ELISA. Briefly, Immulon 4HBX (Nunc,
UK) 96-well plates were coated over night at 4 C with 100 ng/well
of rSmVAL9 diluted in PBS. Plates were blocked with 200 ll of 5%
milk powder/PBS/0.05% Tween-20 for 2 h at 37 C. Blocking solu-
tion was aspirated and plates washed five times with PBS/0.05%
Tween-20. Sera from individual mice were diluted 1:50 in PBS/
0.05% Tween-20/1% BSA and 50 ll added to appropriate wells at
37 C for 90 min. The plates were washed five times and then
50 ll of horse radish peroxidase (HRP) conjugated secondary anti-
body (Sigma) diluted 1:2000 in PBS/0.05% Tween-20/1% BSA were
added to each well for 2 h at 37 C. Plates were again washed five
times and peroxidase signal developed for 14 min with 100 ll of
2,2’-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS)
reagent (Kirkegaard and Perry Laboratories, KPL, USA). The reaction
was terminated with 100 ll of 1% SDS and absorbance at 405 nm
read immediately using a Polarstar Omega plate-reader (BMG
Labtech, UK).
2.14. Mus musculus BMDM//rSmVAL9 co-culture
Bone marrow was collected from the femurs of C57BL/6 mice
and macrophage cultures prepared as previously described
(Truscott et al., 2013). Cultures were allowed to equilibrate for
16 h then treated with rSmVAL9 (10 lg/ml) +/ polymixin B
(10 lg/ml). Unstimulated cells and Tris–glycine (TG) buffer-only
controls (the buffer used to electroelute rSmVAL9) were also main-
tained. After 20 h culture at 37 C, media was removed and cells
immediately lysed in 500 ll/well of TRIzol reagent (Invitrogen)
for RNA extraction and cDNA synthesis as previously described
(Truscott et al., 2013).
2.15. Semi-quantitative (sq) reverse transcription (sqRT)-PCR and
quantitative (q)RT-PCR
rSmVAL9-induced BgMMP1 expression was assessed relative to
the housekeeping Bga actinin in Bge cells. sqRT-PCR primers were
designed for the endogenous control Bga-actinin (NCBI accession
number AF484962) (forward 50-ATG ACA CCC TCC TGT TTC TTC
AAT CTA-30; reverse 50-TAA CTC GGT ACA CGA CCC GTA TTC CTT-
30) and BgMMP1 (NCBI accession number KF287725) (forward 50-
ATG ACA CCC TCC TGT TTC TTC AAT CTA-30; reverse 50-TAA CTC
GGT ACA CGA CCC GTA TTC CTT-30). Thirty-five cycles of PCR were
used to determine BgMMP1 expression differences between Bge
cell treatments (CBSS medium alone, TG buffer alone and rSmVAL9
in TG buffer) and the experiment was performed twice. BgMMP1
expression was normalised to Bga-actinin expression by ImageJ
densitometric analysis of stained amplicons.
qRT-PCR primers were designed for M. musculus MMP2, MMP9,
MMP12, MMP13, MMP14 (MT-MMP1), MMP28, TIMP1 and TIMP2
as well as the endogenous control transcript M. musculus Hprt1
(Supplementary Table S2). qRT-PCR of M. musculus BMDM/ cDNA
was performed using SensiFAST SYBRGreen reagents (Bioline, UK)
on a StepOnePlus Real-Time thermal cycler (Applied Biosystems,
UK) using the fast protocol (10 ll reactions; 0.4 lM each primer,
2 ll of cDNA). Relative MMP and TIMP gene expression regulated
by rSmVAL9 was calculated using the Pfaffl method (Pfaffl, 2001)
where expression of each target gene in a test sample (n = 3) was
calculated as a fold-change with respect to a calibrator cDNA pop-
ulation (untreated BMDM/) and normalised to expression of the
reference gene Hprt1. Data was then transformed (1) such that
a fold-change of 0 demonstrates no change in gene expression
between the compared cDNA populations.
3. Results
3.1. SmVAL9 is developmentally transcribed and post-translationally
glycosylated
In a DNA microarray study designed to characterise the pattern
of S. mansoni transcription throughout 15 lifecycle stages, we
uncovered clusters of genes that were differentially expressed in
snail-residing compared with mouse-residing parasitic forms
(Fitzpatrick et al., 2009). In addition to SmVAL3 (Smp_193710)
and SmVAL7 (Smp_199890), SmVAL9 (Smp_176180) was found
within these gene lists. Closer interrogation of SmVAL9 transcrip-
tion throughout schistosome maturation revealed peak expression
in miracidia, followed by egg and mother sporocyst (48 h post
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in vitro transformation) developmental stages (Fig. 1A). These find-
ings support the qRT-PCR determination of SmVAL9 abundance
previously reported by Chalmers et al. (2008) and indicate that this
group 1 SmVAL may be involved in similar activities within both
snail and mammalian hosts. In order to test this hypothesis, a rSm-
VAL9 was expressed in E. coli cells and purified from insoluble
inclusion bodies by preparatory cell electrophoresis (Fig. 1B).
Polyclonal anti-rSmVAL9 antisera were subsequently raised in
mice and initially used to probe an extract of SEAs by western blot
analysis (Fig. 1C). While anti-rSmVAL9 recognised the 19.3 kDa
rSmVAL9 immunogen, a shift in immunoreactivity to a 25 kDa pro-
tein was observed for native SmVAL9 (nSmVAL9) in the SEA sam-
ple (pre-bleed NMS not recognising either protein or the BSA
control). This increase in molecular mass indicated that egg-
derived nSmVAL9 is post-translationally modified and, as evi-
denced by the smear associated with the immunoreactive band,
likely to be glycosylated.
Native SmVAL9 glycosylation was verified by re-analysing data
previously collected as part of a separate study aiming to identify
and structurally characterise SEA glycoproteins that carry the
unique schistosomal Fuca1–2Fuca1–3HexNAc (Fuc, fucose;
HexNAc, N-acetylhexosaminine) glycan epitope recognised by the
diagnostic antibody 114–4D12-A (Robijn et al., 2007). As part of
this study, we isolated all tryptic glycopeptides in SEA that
contained the Fuca1–2Fuca1–3HexNAc element by affinity chro-
matography (using antibody 114-4D12-A). The glycopeptides were
applied to a RP-nano-LC column coupled to an ion-trap MS/MS sys-
tem and fragmented in the auto-MS/MS mode. A parent-ion of m/z
954.0 [M+3H]3+ in the 16.2–16.5 min elution range was detected,
giving rise to oxonium glycan fragment ions at m/z 350.2 [M+H]+
(deoxyHex1HexNAc1, F1N1) and m/z 496.3 [M+H]+ (F2N1), which
indicate the presence of the terminal difucosylated HexNAc ele-
ment. Further inspection of the collision-induced dissociation
(CID) MS/MS spectrum of the parent ion m/z 954.0 [M+3H]3+,
Fig. 1. Schistosoma mansoni venom allergen-like 9 (SmVAL9) undergoes transcriptional regulation throughout schistosome development, is maximally expressed in miracidia
and is post-translationally modified in eggs. (A) DNA microarray analysis of SmVAL9 expression throughout 15 lifecycle stages. Histogram represents normalised mean
fluorescent intensities + S.D. (n = 3 replicates/lifecycle stage except adult female where n = 2) of SmVAL9 transcript abundance derived from oligonucleotide CD111828 as
described previously (Fitzpatrick et al., 2009). Dashed box encloses schistosome lifecycle stages where SmVAL9 is maximally expressed. Inset drawing represents SmVAL9
(Smp_176180) gene organisation (five exons – black boxes; four introns – black lines) and localisation of oligonucleotide CD111828 to exon 5 (SchistoGeneDB v5.1). (B)
Expression and purification of recombinant SmVAL9 (rSmVAL9) in Escherichia coli cells. The majority of rSmVAL9 is found in insoluble inclusion bodies after induction,
allowing preparatory cell electrophoresis (Prep. Cell) to concentrate and purify large amounts of the protein for murine immunisations and other downstream studies. (C)
Anti-rSmVAL9 recognises the 19.3 kDa rSmVAL9 immunogen and a 25 kDa post-translationally modified, native SmVAL9 (nSmVAL9) from soluble egg antigen. Pre-bleed
normal mouse serum does not recognise either protein or the BSA control.
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which is dominated by glycosidic linkage cleavages (Wuhrer et al.,
2007), indicates the presence of a glycan with the composition
F3H3N3X1 (F, fucose; H, hexose; N, HexNAc; X, xylose) linked to a
peptide of 1192 Da (Fig. 2A). [M+2H]2+ fragment ions are observed
for this peptide carrying a single HexNAc (m/z 698.5) or a Fuc1Hex-
NAc1 disaccharide (m/z 771.5) derived from a mono-fucosylated
chitobiose core structure of an Asn-linked glycan. Furthermore, a
dominant series of [M+2H]2+ fragment ions at m/z 1356.6
(F2H3N3X1-peptide), 1238.6 (F1H3N3X1-peptide), 1182.1
(F1H3N2X1-peptide), 1101.1 (F1H2N2X1-peptide) and 1035.1
(F1H2N2-peptide) are fully in line with the presence of an N-glycan
with a fucosylated, xylosylated trimannosyl core, carrying one
difucosylated N-acetylglucosamine residue forming the mAb
114-4D12-A epitope. The [M+2H]2+ signals observed at m/z
1255.2 (F1H3N2X1-peptide) and 1328.2 (F1H3N2X1-peptide) arise
from the fucose rearrangements commonly observed in CID-MS/
MS of proton adducts of glycans and glycoconjugates (Wuhrer
et al., 2006b).’
To obtain information on the glycopeptide sequence recognised
by mAb 114-4D12-A, an ETD MS/MS spectrum of the same parent
ion m/z 954.0 [M+3H]3+ was recorded (Fig. 2B) in which peptide
cleavages are predominantly observed while leaving the glycosidic
linkages intact (Wuhrer et al., 2007). The c0-type as well as z-type
ions arising from peptide bond cleavages provide partial sequences
of the peptide backbone from the N- and C-terminal side, respec-
tively. As annotated in Fig. 2B, the LSDQC sequence can be read
directly from the ion c4-c9 ion series, while the signals indicated
with z3-z9 read the DSLN(glycan)QA sequence, including the mass
increment of 1665 Da accountable to the glycan. Submitting
sequence tag AQNLSDQC to the NCBI BLAST (nr) database returned
a 100% coverage and identity hit with SmVAL9 (XP_002582201).
This sequence is part of the SmVAL9 tryptic peptide (one missed
cleavage) K71AQNLSDQCK80, containing the N-glycosylation con-
sensus sequence NLS. Taken together, the MS/MS data indicated
that SEA-derived SmVAL9 is modified at Asn74 with a core xylosy-
lated, core fucosylated N-glycan carrying one terminal difucosyl N-
acetylglucosamine residue that forms the epitope recognised by
mAb 114-4D12-A.
3.2. E/S SmVAL9 up-regulates B. glabrata MMP1 expression
To verify whether SmVAL9 translation follows the transcrip-
tional pattern observed during schistosome intramolluscan devel-
opment (Fig. 1A), we performed a quantitative western blot
analysis using anti-rSmVAL9 and protein extracts derived from
miracidia as well as in vitro cultured sporocysts harvested at differ-
ent times (0.5 h–10 days) post-transformation (Fig. 3A). Here, peak
SmVAL9 protein abundance was found in miracidia with diminish-
ing amounts of this group 1 VAL being found in sporocyst stages
during development. These western blot results confirmed the
DNA microarray studies depicted in Fig. 1A and demonstrated that
SmVAL9 transcription and translation patterns correlate. Interest-
ingly, anti-rSmVAL9 analysis of miracidia and sporocyst lifecycle
stages indicated two distinct immunoreactive proteins (inset wes-
tern blot, Fig. 3A). As SmVAL9 bears sequence similarity to other
SmVALs (SmVAL5, 15, 26, 27, 28 and 29) known to be present in
miracidia/sporocyst developmental forms (Wu et al., 2009), it is
possible that one of these bands may represent a cross-reactive
family member. The most likely candidate to be detected by the
anti-rSmVAL9 antisera is SmVAL29, which shares 57% sequence
identity and 71% sequence similarity. Further studies would be
necessary to confirm this hypothesis, however, we cannot rule
out this possibility.
We next utilised the anti-rSmVAL9 antisera to define SmVAL9
localisation within miracidia and 24 h cultured sporocysts
(Fig. 3B). Here, clear anti-rSmVAL9 immunoreactivity (green) was
observed within both miracidium as well as sporocyst samples
and was associated with a diffusely distributed pattern throughout
the parenchyma, perikarya and putative germinal cells (inset box
in Fig. 3B of the 24 h sporocysts). Additional anti-rSmVAL9 immu-
noreactivity was also associated with the miracidia cilia. Pre-bleed
NMS reacted with the surface of both miracidia and sporocyst sam-
ples and is likely due to non-specifically bound mouse IgG acquired
in ovo.
Due to the presence of anti-rSmVAL9 reactivity to miracidia
cilia (Fig. 3B) and the previously described proteomic identification
of SmVAL9 peptides in miracidia/sporocyst transformation prod-
ucts (Wu et al., 2009), we next wanted to assess what components
of our miracidia/sporocyst transformation products contained
native SmVAL9 (Fig. 4). Here, larval transformation proteins
(LTP), shed epidermal plates (EP) and remaining parasite bodies
(Body) were obtained from a typical in vitro miracidia transforma-
tion procedure and incubated with anti-rSmVAL9 antisera during
western blot analysis of solubilised proteins (Fig. 4A). From these
results, two anti-rSmVAL9 immunoreactive proteins were found
in the LTP and Body samples, but not in the EP preparation con-
firming that SmVAL9 was indeed released into the immediate envi-
ronment during larval transformation. These results also indicated
that most, if not all, SmVAL9 was found within non-epidermal
plate containing material, but E/S SmVAL9 could adhere to cilia
in intact miracidia (refer to Fig. 3B).
Having established that SmVAL9 was excreted/secreted during
the process of miracidium to sporocyst transformation (Figs. 3
and 4A) and a previous study demonstrating that mammalian
RTVP-1 (a SmVAL9 homolog) up-regulated gelatinase A/MMP2
expression in glioma cells and influenced the invasion of astocytic
tumors (Rosenzweig et al., 2006), we postulated that a conserved
function in tissue remodelling was possible for E/S SmVAL9. Here,
using the Bge cell line, we specifically examined the ability of rSm-
VAL9 to influence the transcription of a newly discovered B. glabra-
ta matrix metalloproteinase (BgMMP1, NCBI Accession number
KF287725, Supplementary Fig. S1 and Supplementary Table S1).
Identified from the publically available B. glabrata genome
(http://biology.unm.edu/biomphalaria-genome/index.html), the
partial BgMMP1 sequence encodes the conserved catalytic domain
of MMPs including the HxxGHxxxxxH zinc-binding motif and
metalloproteinase-specific serine (S) residue (Bode et al., 1993).
After 24 h of Bge/rSmVAL9 co-culture, we consistently observed
an up-regulation of BgMMP1 expression when compared with
Bge cultures co-cultured with CBSS or TG buffers only (Fig. 4B,
two representative experiments illustrated).
3.3. E/S SmVAL9 is immunogenic during murine schistosomiasis and
differentially regulates M. musculus MMP and TIMP expression in
BMDM/ cultures
As SmVAL9 is a glycoprotein found in SEA (Figs. 1 and 2) and is a
component of E/S products released from eggs (Cass et al., 2007),
we next investigated whether the definitive mammalian host
was capable of recognising this group 1 VAL during experimental
schistosomiasis (Fig. 5). Here, utilising pooled serum samples
obtained from mice infected with S. mansoni for 14 weeks (CMS),
we determined that rSmVAL9 was indeed an IgG target during
chronic schistosomiasis (Fig. 5A). Pooled sera collected from unin-
fected mice (NMS) did not recognise rSmVAL9 in these same wes-
tern blot experiments. A western blot control protein used in these
experiments, BSA, also was not recognised by either CMS or NMS.
We subsequently extended these preliminary western blot
studies to an ELISA format (wells coated with rSmVAL9), which
would allow for a greater number of p.i. time-points to be mea-
sured for anti-rSmVAL9 reactivity. Here, sera samples (four to six
mice/time-point) derived from mice experimentally infected with
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Fig. 2. Schistosoma mansoni venom allergen-like 9 (SmVAL9) is an N-glycosylated soluble egg antigen containing a schistosome-specific, difucosyl modification. (A)
Electrospray ionisation-ion trap MS/MS with collision-induced dissociation and with electron transfer dissociation (B) of the tryptic glycopeptide K71AQNLSDQCK80 from
SmVAL9. The [M+3H]3+ parent ion at m/z 954.0 of the glycopeptide carrying a glycan of composition F3H3N3X1 was selected. Fragment ions are indicated in the figure.
Monoisotopic masses are given. Square, N-acetylglucosamine; circle, mannose; triangle, fucose; star, xylose; pep, peptide moiety.
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S. mansoni for at least 2 and up to 14 weeks were used (Fig. 5B).
While schistosome egg production normally begins at week 5 p.i.
in the murine host, anti-rSmVAL9 IgG responses lagged behind
oviposition and were not measurable (above background; NMS
mean + 3S.D.) until week 8 p.i. This was observed in two indepen-
dent experiments (black histograms, murine infection 1; white
histograms, murine infection 2). From week 8, a gradual rise in
anti-rSmVAL9 IgG titres was observed in both replicate experi-
ments until a peak anti-rSmVAL9 response was measured in the
final 14-week p.i. time-point.
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Having determined that SmVAL9 is recognised during murine
schistosomiasis at time-points after egg deposition, we next asked
whether (similar to Bge cells) this E/S group 1 VAL released in the
definitive host was capable of influencing the expression of genes
involved in tissue remodelling (Fig. 6). As a model to test this
hypothesis, we chose BMDM/ derived from C57BL/6 mouse femurs
(Truscott et al., 2013) and co-cultured those in the presence of
rSmVAL9 (+/ polymyxin B). We specifically assessed the capacity
of rSmVAL9 to differentially regulate the expression of key matrix
metalloproteinases (MmMMP2, MmMMP9, MmMMP12,
MmMMP13, MmMMP14 and MmMMP28) as well as tissue inhib-
itors of metalloproteinases (MmTIMP1 and MmTIMP2) involved
in extracellular matrix remodelling and hepatic fibrosis during
schistosomiasis (Vaillant et al., 2001; Sandler et al., 2003; Madala
et al., 2010; Anthony et al., 2013). Here, we found that rSmVAL9
stimulated the transcription of genes positively involved in degra-
dation of the extracellular matrix (MMP9, MMP13, MMP14/MT-
MMP1 and to a lesser degree MMP2) while simultaneously sup-
pressing the transcription of genes negatively associated with the
same process (TIMP2, MMP12) (Madala et al., 2010; Cardeal
et al., 2012; Chellaiah and Ma, 2013) (Fig. 6). TIMP1 was also highly
induced in rSmVAL9 stimulated BMDM/, while MMP28 transcrip-
tion was minimally affected. Polymyxin B did not affect the
rSmVAL9 transcriptional alterations in BMDM/ suggesting that
our rSmVAL9 produced in E. coli was free from contaminating
endotoxins, the presence of which could have complicated the
interpretation of MmMMP/MmTIMP expression in BMDM/ cul-
tures (Hanania et al., 2012). Taken together (and similar to what
was found in the Bge system, Fig. 4), the rSmVAL9/BMDM/ co-
culture experiments suggested that E/S SmVAL9 manipulates host
cell transcription of MMPs/TIMPs and this activity may contribute
to an environment suitable for egg translocation and lifecycle
transmission.
4. Discussion
Functional characterisation of the schistosome molecules/
metabolites involved in molluscan and mammalian host interac-
tions will help reveal how these highly successful parasites estab-
lish and maintain the biomedically-important, neglected tropical
disease schistosomiasis. In this regard, recent studies of polymor-
phic mucins (Mone et al., 2010), E/S helminth defence molecules
(Thivierge et al., 2013), omega-1 (Everts et al., 2009; Steinfelder
et al., 2009), IPSE/alpha-1 (Schramm et al., 2003) and regurgitated
haemozoin (Truscott et al., 2013) have all detailed the contributory
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Fig. 4. Schistosoma mansoni venom allergen-like 9 (SmVAL9) released during the process of miracidia to sporocyst transformation induces Biomphalaria glabrata matrix
metalloproteinase expression. (A) Native SmVAL9 is released into medium during early larval cultivation. Western blot showing immunoreactive native (n)SmVAL9 in culture
supernatant containing larval transformation proteins and in whole body homogenates (Body), but not in shed epidermal plates. Absence of epidermal plates
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(Bge) cell line to rSmVAL9 (0.8 lg/ml) stimulates matrix metalloproteinase 1 (BgMMP1) transcription. Using B. glabrata a (Bga)-actinin as a reference, relative intensity of the
BgMMP1 amplicon was greater in rSmVAL9-exposed Bge cells compared with cells treated with snail saline alone (CBSS) or rSmVAL9 Tris–glycine buffer alone (TG buffer).
Results of two independent experiments are shown with inset histogram representing mean densitometric values of BgMMP1/Bga-actinin expression + S.D.
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role of developmentally-regulated schistosome gene products/
metabolites in manipulating the (immuno) biology of intermediate
or definitive host cells. Extending these functional investigations to
other schistosome biomolecules found at the host/parasite
interface will undoubtedly increase the number of targets consid-
ered for next-generation chemotherapeutic (drugs), immunothera-
peutic (immunomodulators) or immunoprophylactic (vaccines)
strategies. As part of our ongoing activities in this area
(Fitzpatrick et al., 2009; Geyer et al., 2011; Everts et al., 2012;
Meevissen et al., 2012; Yoshino et al., 2012; Peterson et al., 2013;
Truscott et al., 2013), we herein describe the activity of a SmVAL9
molecule on both Bge cells and M. musculus BMDM/.
The 29 SmVALs encoded in the S. mansoni genome (v5.2) are
related to an often described, but poorly understood, family of pro-
teins (Sperm Coating Protein/Tpx-1/Ag5/PR-1/Sc7; SCP/TAPS)
distributed throughout the Archaea, Eubacteria and Eukarya
(Chalmers and Hoffmann, 2012). Within the parasitic Nematoda,
some E/S SCP/TAPSmembers have been implicated in immunomod-
ulatory activities including platelet aggregation inhibition (Del Valle
et al., 2003), neutrophil chemotaxis manipulation (Bower et al.,
2008), neutrophil binding (Moyle et al., 1994) and angiogenesis
stimulation (Tawe et al., 2000). It is thought that these activities help
the invading L3s establish infection, modulate potentially deleteri-
ous host immune responses and induce environmental conditions
suitable for survival (Cantacessi et al., 2009). As schistosomes
encounter similar immunological/environmental challenges during
lifecycle progression through molluscan and mammalian hosts, we
postulated that E/S group 1 SmVALs could function in a similar
immunomodulatory/environmentally-altering vein. SmVAL9 was
chosen as the representative group 1 protein with which to investi-
gate this hypothesis due to its presence in both mammalian-host
inhabiting egg (Cass et al., 2007) and molluscan-host residing mira-
cidia/sporocyst excretions/secretions (Wu et al., 2009).
Our results confirm the presence of SmVAL9 in both egg and
miracidia/sporocyst lifecycle stages (Figs. 1 and 2). However, sev-
eral new observations about this developmentally-regulated group
1 VAL were recorded in this study. While many O-linked glycans
found in SEA contain the double fucose containing epitope
described here (Robijn et al., 2007) and multi-fucosylated elements
are present on a subset of SEA-derived N-linked glycans (Khoo
et al., 1997; Hokke et al., 2007), we have now identified for the first
time a specific carrier, SmVAL9, that presents this particular
Fuca1–2Fuc element (Fig. 2). Furthermore, full MS/MS character-
isation of the SmVAL9 tryptic N-glycopeptide illustrates a glycosyl-
ation quite distinct to the glycosylation patterns described for
three other major egg antigens including omega-1, IPSE/alpha-1
and kappa-5. E/S omega-1 and IPSE/alpha-1 both contain Galb1–
4(Fuca1–3)GlcNAc (Lewis X) antigens aaa(Wuhrer et al., 2006a;
Meevissen et al., 2010), while non-E/S kappa-5 contains multiple
GalbNAc1–4GlcNAc (LDN) termini (Meevissen et al., 2011). The
absence of Lewis X and LDN elements, together with the presence
of the difucosylated terminal N-linked motif, suggests that
SmVAL9 interacts with one or more C-type lectin receptor different
from those that bind omega-1, IPSE/alpha-1 or kappa-5 (Meevissen
et al., 2012). A lectin receptor that preferentially binds the difuco-
syl element of SmVAL9 has not yet been identified.
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Fig. 5. Schistosoma mansoni venom allergen-like 9 (SmVAL9) is an immunogenic IgG target recognised during experimental murine schistosomiasis. (A) Ten micrograms of
recombinant (r)SmVAL9 or BSA were electrophoresed, blotted onto polyvinyl difluoride and probed with chronic mouse serum; obtained from mice experimentally infected
for 14 weeks; 50 cercariae/mouse or normal mouse serum (both at 1:150). A 19.3 kDa, immunoreactive protein is specifically observed in the rSmVAL9 lane when probed
with chronic mouse serum, but not normal mouse serum. (B) ELISA measurement of anti-rSmVAL9 IgG reactivity in mice experimentally infected (50 cercariae/mouse) with S.
mansoni. Histograms represent mean (+S.D.) anti-rSmVAL9 total IgG absorbance (four to six animals/time-point) measured in mice at 2–14 weeks p.i. from two repeat
experiments (black histograms, murine infection 1; white histograms, murine infection 2). Dashed line represents mean anti-rSmVAL9 reactivity + 3 S.D. derived from normal
mouse serum.
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When considering where anti-rSmVAL9 reactivity is found
within miracidia/sporocyst lifecycle stages, our results indicate dif-
fuse SmVAL9 localisation to parenchyma, perikaya and germinal
cells (Fig. 3B). As the miR-137 target RTVP-1 (a SCP/TAPS protein
related to SmVAL9) has recently been found to influence the self-
renewal and differentiation of glioblastoma stem cells (Bier et al.,
2013), SmVAL9 localisation to this parasite cell population is
intriguing. This is especially true in light of the recent description
of SmVAL22 expression in sporocyst germinal cell populations
(Wang et al., 2013). Our data supports the association of SmVALs
in sporocyst germinal cells and expands the repertoire found in
this important self-renewing schistosome cell population main-
tained throughout parasite development (Collins et al., 2013).
Importantly, SmVAL9 excretion/secretion during miracidia/sporo-
cyst transformation (Fig. 3C) as well as SmVAL9 excretion/secre-
tion from eggs (Cass et al., 2007) indicates another possible
function(s) (additional to germinal cell biology) related to para-
site/host interactions. We therefore explored this hypothesis using
two different host cell models (molluscan Bge cells and mamma-
lian BMDM/).
In both models (Figs. 4B and 6), the ability of rSmVAL9 to differ-
entially regulate host cell MMP expression was specifically
explored due to the capacity of RTVP-1 to induce the up-regulation
and secretion of MMP2 from glioma cells (Rosenzweig et al., 2006).
This RTVP-1 mediated MMP2 secretion facilitates ECM remodelling
and influences the invasion of astrocytic tumors. As miracidia to
sporocyst transformation in B. glabrata involves parasite invasion
and host ECM remodelling (Borges and Andrade, 2003), a likely
conserved role for E/S SmVAL9 in regulating MMP expression
was postulated. After first identifying a bona fide B. glabrata
MMP (BgMMP1) in the B. glabrata genome (http://biol-
ogy.unm.edu/biomphalaria-genome/index.html), with high
sequence similarity to membrane-type 3 MMP (also known as
MMP16; (Shi et al., 2008; Sabeh et al., 2009)) database hits (Sup-
plementary Fig. S1 and Supplementary Table S2), we assessed the
capacity of rSmVAL9 to regulate its expression in Bge cells by
sqRT-PCR (Fig. 3D). Clear induction of BgMMP1 transcription was
seen in Bge cells stimulated with rSmVAL9 at a level greater than
that measured in Bge cultures stimulated with buffer controls
and this activity was independent of the presence of the double
fucose containing glycan found on native SmVAL9 (Fig. 2). It is
known that mammalian MMP16 activates MMP2 into an active,
ECM degrading zymogen (Astarci et al., 2012), favouring the inva-
sive potential of cells from one locality to another (Stamenkovic,
2003). While we have yet to elucidate the full MMP repertoire
(including a MMP2 like homolog) encoded in the B. glabrata gen-
ome or to determine whether rSmVAL9-induced BgMMP1
(MMP16-like homolog) transcription correlates with enzymatic
activity in Bge cells, our cautious interpretation of these findings
implicates a potential function of E/S SmVAL9 in creating an envi-
ronment suitable for miracidia invasion and sporocyst migration
throughout Biomphalaria tissues. Another potential benefit for
larval SmVAL9 induction of MMPs stems from the fact that this
enzyme family contains conserved haeme-binding domains
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(haemopexin-like domains; (Piccard et al., 2007)) capable of bind-
ing/sequestering Fe-containing haem moieties comprising snail
haemoglobin, thereby disrupting potentially lethal anti-parasite
redox reactions (Bayne et al., 2001; Tolosano and Altruda, 2002).
Additional evidence to support a host modulatory role for
SmVAL9 was derived from parallel experiments in rSmVAL9/
BMDM/ co-cultures where the expression of several MMPs and
TIMPs were investigated by qRT-PCR (Fig. 6). A previous study
demonstrated that SEA was capable of inducing MMP9 expression
in LX-2 cells (a human hepatic stellate cell line) with this activity
postulated to originate in the excretory/secretory products
released from the eggs (Anthony et al., 2013). Furthermore, as tis-
sue-degrading MMP9, MMP2 and MMP13 function is regulated by
MMP12 activity during granulomatous pathology (Madala et al.,
2010), E/S SmVAL9 from eggs could behave as a pro-ECM remodel-
ling factor by manipulating the reciprocal expression of these
MMPs. Our findings are entirely consistent with this hypothesis
and those results reported by Madala et al. (2010), Cardeal et al.
(2012) and Chellaiah and Ma (2013), suggesting that excretory/
secretory SmVAL9 activates the differential expression of MMPs/
TIMPs instrumental in tissue remodelling. This activity likely con-
tributes to an environment suitable for the translocation of eggs
across the intestinal lumen and/or the development of immunolog-
ically-regulated granulomatous pathology (Hoffmann et al., 2002).
Host IgG recognition of SmVAL9 may participate in regulation of
these processes (Fig. 4) by decreasing the amount of circulating/tis-
sue-trapped SmVAL9. However, similar to the Bge studies, these
interpretations need tempering until active MMP secretion from
rSmVAL9 stimulated BMDM/s is characterised. Irrespective, we
contend that both Bge and BMDM/ models demonstrate that
SmVAL9 is capable of differentially regulating host cell MMP/TIMP
transcription and that this activity may participate in the co-
evolved survival strategies employed by schistosomes during
host/parasite interactions.
Acknowledgements
This work was supported by research grants awarded to KFH
(Wellcome Trust, UK, WT084273/Z/07/Z), to TPY (National Insti-
tutes of Health (NIH), USA, 2RO1 AI015503) and to CHH (Nether-
lands Genomics Initiative 050-71-022). The Erasmus programme
(UK) supported MK’s contribution to this project. Infected mice
(NMRI strain) were provided to TPY by the Biomedical Research
Institute (BRI) under NIH-NIAID, USA contract number
HHSN272201000005I. We thank Ms Julie Hirst from Aberystwyth
University, UK, L.A. Gonzalez and R. Geske from University of Wis-
consin, USA and Mrs. Janneke Kos-van Oosterhoud from Leiden
University Medical Centre (LUMC), Netherlands for assistance in
schistosome lifecycle maintenance as well as mouse and snail hus-
bandry. We also thank Ms Isabel Catalina and Carolien Koeleman
from LUMC for expert LC–MS/MS assistance as well as members
of the Hoffmann, Yoshino and Hokke laboratories for many helpful
comments throughout this project.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.ijpara.2014.04.
002.
References
Anthony, B.J., James, K.R., Gobert, G.N., Ramm, G.A., McManus, D.P., 2013.
Schistosoma eggs induce a proinflammatory, anti-fibrogenic phenotype in
hepatic stellate cells. PloS One 8, e68479.
Astarci, E., Erson-Bensan, A.E., Banerjee, S., 2012. Matrix metalloprotease 16
expression is downregulated by microRNA-146a in spontaneously
differentiating Caco-2 cells. Dev Growth Differ 54, 216–226.
Barry, M.A., Simon, G.G., Mistry, N., Hotez, P.J., 2013. Global trends in neglected
tropical disease control and elimination: impact on child health. Arch Dis Child
98, 635–641.
Basch, P.F., 1991. Schistosomes: development, reproduction, and host relations.
Oxford University Press Inc, New York.
Bayne, C.J., Hahn, U.K., Bender, R.C., 2001. Mechanisms of molluscan host resistance
and of parasite strategies for survival. Parasitology 123 (Suppl.), S159–S167.
Bier, A., Giladi, N., Kronfeld, N., Lee, H.K., Cazacu, S., Finniss, S., Xiang, C., Poisson, L.,
de Carvalho, A.C., Slavin, S., Jacoby, E., Yalon, M., Toren, A., Mikkelsen, T., Brodie,
C., 2013. MicroRNA-137 is downregulated in glioblastoma and inhibits the
stemness of glioma stem cells by targeting RTVP-1. Oncotarget 4, 665–676.
Bode, W., Gomis-Ruth, F.X., Stockler, W., 1993. Astacins, serralysins, snake venom
and matrix metalloproteinases exhibit identical zinc-binding environments
(HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a
common family, the ‘metzincins’. FEBS Lett 331, 134–140.
Borges, C.M., Andrade, Z.A., 2003. Extra-cellular matrix changes in Schistosoma
mansoni-infected Biomphalaria glabrata. Mem Inst Oswaldo Cruz 98, 135–139.
Bower, M.A., Constant, S.L., Mendez, S., 2008. Necator americanus: the Na-ASP-2
protein secreted by the infective larvae induces neutrophil recruitment in vivo
and in vitro. Exp Parasitol 118, 569–575.
Cantacessi, C., Campbell, B.E., Visser, A., Geldhof, P., Nolan, M.J., Nisbet, A.J.,
Matthews, J.B., Loukas, A., Hofmann, A., Otranto, D., Sternberg, P.W., Gasser, R.B.,
2009. A portrait of the ‘‘SCP/TAPS’’ proteins of eukaryotes–developing a
framework for fundamental research and biotechnological outcomes.
Biotechnol Adv 27, 376–388.
Cardeal, L.B., Boccardo, E., Termini, L., Rabachini, T., Andreoli, M.A., Di Loreto, C.,
Longatto Filho, A., Villa, L.L., Maria-Engler, S.S., 2012. HPV16 oncoproteins
induce MMPs/RECK-TIMP-2 imbalance in primary keratinocytes: possible
implications in cervical carcinogenesis. PloS One 7, e33585.
Cass, C.L., Johnson, J.R., Califf, L.L., Xu, T., Hernandez, H.J., Stadecker, M.J., Yates 3rd,
J.R., Williams, D.L., 2007. Proteomic analysis of Schistosoma mansoni egg
secretions. Mol Biochem Parasitol 155, 84–93.
Chalmers, I.W., Hoffmann, K.F., 2012. Platyhelminth Venom Allergen-Like (VAL)
proteins: revealing structural diversity, class-specific features and biological
associations across the phylum. Parasitology 139, 1231–1245.
Chalmers, I.W., McArdle, A.J., Coulson, R.M., Wagner, M.A., Schmid, R., Hirai, H.,
Hoffmann, K.F., 2008. Developmentally regulated expression, alternative
splicing and distinct sub-groupings in members of the Schistosoma mansoni
venom allergen-like (SmVAL) gene family. BMC Genomics 9, 89.
Chellaiah, M.A., Ma, T., 2013. Membrane localization of membrane type 1 matrix
metalloproteinase by CD44 regulates the activation of pro-matrix
metalloproteinase 9 in osteoclasts. Biomed Res Int 2013, 302392.
Cheng, G., Luo, R., Hu, C., Cao, J., Jin, Y., 2013. Deep sequencing-based identification
of pathogen-specific microRNAs in the plasma of rabbits infected with
Schistosoma japonicum. Parasitology, 1–11.
Chernin, E., 1963. Observations on hearts explanted in vitro from the snail
Australorbis glabratus. J Parasitol 49, 353–364.
Collins 3rd, J.J., Wang, B., Lambrus, B.G., Tharp, M.E., Iyer, H., Newmark, P.A., 2013.
Adult somatic stem cells in the human parasite Schistosoma mansoni. Nature
494, 476–479.
Curwen, R.S., Ashton, P.D., Sundaralingam, S., Wilson, R.A., 2006. Identification of
novel proteases and immunomodulators in the secretions of schistosome
cercariae that facilitate host entry. Mol Cell Proteomics 5, 835–844.
Da’dara, A., Skelly, P.J., 2011. Manipulation of vascular function by blood flukes?
Blood Rev 25, 175–179.
de Morree, A., Hensbergen, P.J., van Haagen, H.H., Dragan, I., Deelder, A.M., t Hoen,
P.A., Frants, R.R., van der Maarel, S.M., 2010. Proteomic analysis of the dysferlin
protein complex unveils its importance for sarcolemmal maintenance and
integrity. PloS One 5, e13854.
Del Valle, A., Jones, B.F., Harrison, L.M., Chadderdon, R.C., Cappello, M., 2003.
Isolation and molecular cloning of a secreted hookworm platelet inhibitor from
adult Ancylostoma caninum. Mol Biochem Parasitol 129, 167–177.
Edgar, R.C., 2004. MUSCLE: multiple sequence alignment with high accuracy and
high throughput. Nucleic Acids Res 32, 1792–1797.
Everts, B., Hussaarts, L., Driessen, N.N., Meevissen, M.H., Schramm, G., van der Ham,
A.J., van der Hoeven, B., Scholzen, T., Burgdorf, S., Mohrs, M., Pearce, E.J., Hokke,
C.H., Haas, H., Smits, H.H., Yazdanbakhsh, M., 2012. Schistosome-derived
omega-1 drives Th2 polarization by suppressing protein synthesis following
internalization by the mannose receptor. J Exp Med 209, 1753–1767, S1751.
Everts, B., Perona-Wright, G., Smits, H.H., Hokke, C.H., van der Ham, A.J.,
Fitzsimmons, C.M., Doenhoff, M.J., van der Bosch, J., Mohrs, K., Haas, H.,
Mohrs, M., Yazdanbakhsh, M., Schramm, G., 2009. Omega-1, a glycoprotein
secreted by Schistosoma mansoni eggs, drives Th2 responses. J Exp Med 206,
1673–1680.
Farias, L.P., Rodrigues, D., Cunna, V., Rofatto, H.K., Faquim-Mauro, E.L., Leite, L.C.,
2012. Schistosoma mansoni venom allergen like proteins present differential
allergic responses in a murine model of airway inflammation. PLoS Negl Trop
Dis 6, e1510.
Fitzpatrick, J.M., Peak, E., Perally, S., Chalmers, I.W., Barrett, J., Yoshino, T.P., Ivens,
A.C., Hoffmann, K.F., 2009. Anti-schistosomal intervention targets identified by
lifecycle transcriptomic analyses. PLoS Negl Trop Dis 3, e543.
Geyer, K.K., Hoffmann, K.F., 2012. Epigenetics: a key regulator of platyhelminth
developmental biology? Int J Parasitol 42, 221–224.
562 T.P. Yoshino et al. / International Journal for Parasitology 44 (2014) 551–563
Author's personal copy
Geyer, K.K., Rodriguez Lopez, C.M., Chalmers, I.W., Munshi, S.E., Truscott, M., Heald,
J., Wilkinson, M.J., Hoffmann, K.F., 2011. Cytosine methylation regulates
oviposition in the pathogenic blood fluke Schistosoma mansoni. Nat Commun
2, 424.
Han, Z.G., Brindley, P.J., Wang, S.Y., Chen, Z., 2009. Schistosoma genomics: new
perspectives on schistosome biology and host-parasite interaction. Annu Rev
Genomics Hum Genet 10, 211–240.
Hanania, R., Sun, H.S., Xu, K., Pustylnik, S., Jeganathan, S., Harrison, R.E., 2012.
Classically activated macrophages use stable microtubules for matrix
metalloproteinase-9 (MMP-9) secretion. J Biol Chem 287, 8468–8483.
Hansell, E., Braschi, S., Medzihradszky, K.F., Sajid, M., Debnath, M., Ingram, J., Lim,
K.C., McKerrow, J.H., 2008. Proteomic analysis of skin invasion by blood fluke
larvae. PLoS Negl Trop Dis 2, e262.
Hoffmann, K.F., Strand, M., 1996. Molecular identification of a Schistosoma mansoni
tegumental protein with similarity to cytoplasmic dynein light chains. J Biol
Chem 271, 26117–26123.
Hoffmann, K.F., Wynn, T.A., Dunne, D.W., 2002. Cytokine-mediated host responses
during schistosome infections; walking the fine line between immunological
control and immunopathology. Adv Parasitol 52, 265–307.
Hokke, C.H., Deelder, A.M., 2001. Schistosome glycoconjugates in host-parasite
interplay. Glycoconj J 18, 573–587.
Hokke, C.H., Deelder, A.M., Hoffmann, K.F., Wuhrer, M., 2007. Glycomics-driven
discoveries in schistosome research. Exp Parasitol 117, 275–283.
Khoo, K.H., Chatterjee, D., Caulfield, J.P., Morris, H.R., Dell, A., 1997. Structural
mapping of the glycans from the egg glycoproteins of Schistosoma mansoni and
Schistosoma japonicum: identification of novel core structures and terminal
sequences. Glycobiology 7, 663–677.
Madala, S.K., Pesce, J.T., Ramalingam, T.R., Wilson, M.S., Minnicozzi, S., Cheever,
A.W., Thompson, R.W., Mentink-Kane, M.M., Wynn, T.A., 2010. Matrix
metalloproteinase 12-deficiency augments extracellular matrix degrading
metalloproteinases and attenuates IL-13-dependent fibrosis. J Immunol 184,
3955–3963.
Marchler-Bauer, A., Lu, S., Anderson, J.B., Chitsaz, F., Derbyshire, M.K., DeWeese-
Scott, C., Fong, J.H., Geer, L.Y., Geer, R.C., Gonzales, N.R., Gwadz, M., Hurwitz,
D.I., Jackson, J.D., Ke, Z., Lanczycki, C.J., Lu, F., Marchler, G.H., Mullokandov, M.,
Omelchenko, M.V., Robertson, C.L., Song, J.S., Thanki, N., Yamashita, R.A.,
Zhang, D., Zhang, N., Zheng, C., Bryant, S.H., 2011. CDD: a Conserved Domain
Database for the functional annotation of proteins. Nucleic Acids Res 39,
D225–D229.
Mathieson, W., Wilson, R.A., 2010. A comparative proteomic study of the
undeveloped and developed Schistosoma mansoni egg and its contents: the
miracidium, hatch fluid and secretions. Int J Parasitol 40, 617–628.
Meevissen, M.H., Balog, C.I., Koeleman, C.A., Doenhoff, M.J., Schramm, G., Haas, H.,
Deelder, A.M., Wuhrer, M., Hokke, C.H., 2011. Targeted glycoproteomic analysis
reveals that kappa-5 is a major, uniquely glycosylated component of
Schistosoma mansoni egg antigens. Mol Cell Proteomics 10 (5), M110.005710.
Meevissen, M.H., Driessen, N.N., Smits, H.H., Versteegh, R., van Vliet, S.J., van Kooyk,
Y., Schramm, G., Deelder, A.M., Haas, H., Yazdanbakhsh, M., Hokke, C.H., 2012.
Specific glycan elements determine differential binding of individual egg
glycoproteins of the human parasite Schistosoma mansoni by host C-type
lectin receptors. Int J Parasitol 42, 269–277.
Meevissen, M.H., Wuhrer, M., Doenhoff, M.J., Schramm, G., Haas, H., Deelder, A.M.,
Hokke, C.H., 2010. Structural characterization of glycans on omega-1, a major
Schistosoma mansoni egg glycoprotein that drives Th2 responses. J Proteome Res
9, 2630–2642.
Mone, Y., Gourbal, B., Duval, D., Du Pasquier, L., Kieffer-Jaquinod, S., Mitta, G., 2010.
A large repertoire of parasite epitopes matched by a large repertoire of host
immune receptors in an invertebrate host/parasite model. PLoS Negl Trop Dis 4,
e813.
Moyle, M., Foster, D.L., McGrath, D.E., Brown, S.M., Laroche, Y., De Meutter, J.,
Stanssens, P., Bogowitz, C.A., Fried, V.A., Ely, J.A., et al., 1994. A hookworm
glycoprotein that inhibits neutrophil function is a ligand of the integrin CD11b/
CD18. J Biol Chem 269, 10008–10015.
Nawaratna, S.S., McManus, D.P., Moertel, L., Gobert, G.N., Jones, M.K., 2011. Gene
atlasing of digestive and reproductive tissues in Schistosoma mansoni. PLoS Negl
Trop Dis 5, e1043.
Peterson, N.A., Anderson, T.K., Yoshino, T.P., 2013. In silico analysis of the
fucosylation-associated genome of the human blood fluke Schistosoma
mansoni: cloning and characterization of the fucosyltransferase multigene
family. PloS One 8, e63299.
Peterson, N.A., Hokke, C.H., Deelder, A.M., Yoshino, T.P., 2009. Glycotope analysis in
miracidia and primary sporocysts of Schistosoma mansoni: differential
expression during the miracidium-to-sporocyst transformation. Int J Parasitol
39, 1331–1344.
Pfaffl, M.W., 2001. A new mathematical model for relative quantification in real-
time RT-PCR. Nucleic Acids Res 29, e45.
Piccard, H., Van den Steen, P.E., Opdenakker, G., 2007. Hemopexin domains as
multifunctional liganding modules in matrix metalloproteinases and other
proteins. J Leukoc Biol 81, 870–892.
Robijn, M.L., Koeleman, C.A., Wuhrer, M., Royle, L., Geyer, R., Dwek, R.A., Rudd, P.M.,
Deelder, A.M., Hokke, C.H., 2007. Targeted identification of a unique glycan
epitope of Schistosoma mansoni egg antigens using a diagnostic antibody. Mol
Biochem Parasitol 151, 148–161.
Rofatto, H.K., Parker-Manuel, S.J., Barbosa, T.C., Tararam, C.A., Alan Wilson, R., Leite,
L.C., Farias, L.P., 2012. Tissue expression patterns of Schistosoma mansoni Venom
Allergen-Like proteins 6 and 7. Int J Parasitol 42, 613–620.
Rosenzweig, T., Ziv-Av, A., Xiang, C., Lu, W., Cazacu, S., Taler, D., Miller, C.G., Reich, R.,
Shoshan, Y., Anikster, Y., Kazimirsky, G., Sarid, R., Brodie, C., 2006. Related to
testes-specific, vespid, and pathogenesis protein-1 (RTVP-1) is overexpressed in
gliomas and regulates the growth, survival, and invasion of glioma cells. Cancer
Res 66, 4139–4148.
Sabeh, F., Li, X.Y., Saunders, T.L., Rowe, R.G., Weiss, S.J., 2009. Secreted versus
membrane-anchored collagenases: relative roles in fibroblast-dependent
collagenolysis and invasion. J Biol Chem 284, 23001–23011.
Sandler, N.G., Mentink-Kane, M.M., Cheever, A.W., Wynn, T.A., 2003. Global gene
expression profiles during acute pathogen-induced pulmonary inflammation
reveal divergent roles for Th1 and Th2 responses in tissue repair. J Immunol
171, 3655–3667.
Schramm, G., Falcone, F.H., Gronow, A., Haisch, K., Mamat, U., Doenhoff, M.J.,
Oliveira, G., Galle, J., Dahinden, C.A., Haas, H., 2003. Molecular characterization
of an interleukin-4-inducing factor from Schistosoma mansoni eggs. J Biol Chem
278, 18384–18392.
Shi, J., Son, M.Y., Yamada, S., Szabova, L., Kahan, S., Chrysovergis, K., Wolf, L., Surmak,
A., Holmbeck, K., 2008. Membrane-type MMPs enable extracellular matrix
permissiveness and mesenchymal cell proliferation during embryogenesis. Dev
Biol 313, 196–209.
Stamenkovic, I., 2003. Extracellular matrix remodelling: the role of matrix
metalloproteinases. J Pathol 200, 448–464.
Steinfelder, S., Andersen, J.F., Cannons, J.L., Feng, C.G., Joshi, M., Dwyer, D., Caspar, P.,
Schwartzberg, P.L., Sher, A., Jankovic, D., 2009. The major component in
schistosome eggs responsible for conditioning dendritic cells for Th2
polarization is a T2 ribonuclease (omega-1). J Exp Med 206, 1681–1690.
Tawe, W., Pearlman, E., Unnasch, T.R., Lustigman, S., 2000. Angiogenic activity of
Onchocerca volvulus recombinant proteins similar to vespid venom antigen 5.
Mol Biochem Parasitol 109, 91–99.
Thivierge, K., Cotton, S., Schaefer, D.A., Riggs, M.W., To, J., Lund, M.E., Robinson,
M.W., Dalton, J.P., Donnelly, S.M., 2013. Cathelicidin-like Helminth Defence
Molecules (HDMs): absence of cytotoxic, anti-microbial and anti-protozoan
activities imply a specific adaptation to immune modulation. PLoS Negl Trop
Dis 7, e2307.
Tolosano, E., Altruda, F., 2002. Hemopexin: structure, function, and regulation. DNA
Cell Biol 21, 297–306.
Truscott, M., Evans, D.A., Gunn, M., Hoffmann, K.F., 2013. Schistosoma mansoni
Hemozoin Modulates Alternative activation of macrophages via specific
suppression of retnla expression and secretion. Infect Immun 81, 133–142.
Vaillant, B., Chiaramonte, M.G., Cheever, A.W., Soloway, P.D., Wynn, T.A., 2001.
Regulation of hepatic fibrosis and extracellular matrix genes by the th response:
new insight into the role of tissue inhibitors of matrix metalloproteinases. J
Immunol 167, 7017–7026.
van Balkom, B.W., van Gestel, R.A., Brouwers, J.F., Krijgsveld, J., Tielens, A.G., Heck,
A.J., van Hellemond, J.J., 2005. Mass spectrometric analysis of the Schistosoma
mansoni tegumental sub-proteome. J Proteome Res 4, 958–966.
van Die, I., Cummings, R.D., 2010. Glycan gimmickry by parasitic helminths: a
strategy for modulating the host immune response? Glycobiology 20, 2–12.
Wang, B., Collins 3rd, J.J., Newmark, P.A., 2013. Functional genomic characterization
of neoblast-like stem cells in larval Schistosoma mansoni. Elife 2, e00768.
Wu, X.J., Sabat, G., Brown, J.F., Zhang, M., Taft, A., Peterson, N., Harms, A., Yoshino,
T.P., 2009. Proteomic analysis of Schistosoma mansoni proteins released during
in vitro miracidium-to-sporocyst transformation. Mol Biochem Parasitol 164,
32–44.
Wuhrer, M., Balog, C.I., Catalina, M.I., Jones, F.M., Schramm, G., Haas, H., Doenhoff,
M.J., Dunne, D.W., Deelder, A.M., Hokke, C.H., 2006a. IPSE/alpha-1, a major
secretory glycoprotein antigen from schistosome eggs, expresses the Lewis X
motif on core-difucosylated N-glycans. FEBS J 273, 2276–2292.
Wuhrer, M., Catalina, M.I., Deelder, A.M., Hokke, C.H., 2007. Glycoproteomics based
on tandem mass spectrometry of glycopeptides. J Chromatogr B Analyt Technol
Biomed Life Sci 849, 115–128.
Wuhrer, M., Koeleman, C.A., Hokke, C.H., Deelder, A.M., 2006b. Mass spectrometry
of proton adducts of fucosylated N-glycans: fucose transfer between antennae
gives rise to misleading fragments. Rapid Commun Mass Spectrom 20, 1747–
1754.
Yoshino, T.P., Laursen, J.R., 1995. Production of Schistosoma mansoni daughter
sporocysts from mother sporocysts maintained in synxenic culture with
Biomphalaria glabrata embryonic (Bge) cells. J Parasitol 81, 714–722.
Yoshino, T.P., Wu, X.J., Liu, H., Gonzalez, L.A., Deelder, A.M., Hokke, C.H., 2012.
Glycotope sharing between snail hemolymph and larval schistosomes: larval
transformation products alter shared glycan patterns of plasma proteins. PLoS
Negl Trop Dis 6, e1569.
T.P. Yoshino et al. / International Journal for Parasitology 44 (2014) 551–563 563
